Reward summation and the effects of dopamine D1 and D2 agonists and antagonists on fixed-interval responding for brain stimulation
References (58)
- et al.
The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors
Eur. J. Pharmacol.
(1986) Domperidone
Gen. Pharmacol.
(1988)- et al.
Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics
Life Sci.
(1984) - et al.
Effects of agonists and antagonists of D1 and D2 dopamine receptors on self-stimulation of the medial prefrontal cortex in the rat
Pharmacol. Biochem. Behav.
(1983) The role of the dopaminergic projections in MFB self-stimulation
Behav. Brain Res.
(1986)- et al.
Affinity for the dopamine D2 receptor predicts neuroleptic potency in blocking the reinforcing effect of MFB stimulation
Pharmacol. Biochem. Behav.
(1983) - et al.
Catecholamine systems as the neural substrate for intra-cranial self-stimulation: A hypothesis
Brain Res.
(1974) - et al.
The D1 dopamine receptor antagonist, SCH 23390, reduces locomotor activity and rearing in rats
Pharmacol. Biochem. Behav.
(1985) - et al.
Parametric manipulations and fixed-interval self-stimulation
Physiol. Behav.
(1992) - et al.
Reward summation and the effects of pimozide, clonidine, and amphetamine on fixed-interval responding for brain stimulation
Pharmacol. Biochem. Behav.
(1992)
SCH 23390—the first selective dopamine D−1 antagonist
Eur. J. Pharmacol.
The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat
Neurosci. Lett.
Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity
Biochem. Pharmacol.
Effects of apomorphine on self-stimulation responding: Does the drug mimic the current?
Brain Res.
Blockade of D−1 receptors bu SCH 23390 antagonizes morphine- and amphetamine-induced place preference conditioning
Eur. J. Pharmacol.
Discriminating between reward and performance: A critical review of intracranial self-stimulation methodology
Neurosci. Biobehav. Rev.
Dopamine D-1 and D-2 receptors in relation to reward and performance: A case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs
Prog. Neurobiol.
Reduction of the rewarding effect of brain stimulation by a blockade of dopamine D1 receptor with SCH 23390
Pharmacol. Biochem. Behav.
GBR 12909 reverses the SCH 23390 inhibition of rewarding effects of brain stimulation
Eur. J. Pharmacol.
Schedule-controlled brain self-stimulation: Has it utility for behavioral pharmacology?
Neurosci. Biobehav. Rev.
The central effects of a novel dopamine agonist
Eur. J. Pharmacol.
Neuroleptics and brain self-stimulation behavior
Int. Rev. Neurobiol.
Catecholamine theories of reward: A critical review
Brain Res.
Self-stimulation and psychotropic drugs: A methodological and conceptual critique
Effects of extinction, pimozide, SCH 23390, and metaclopramide on food-rewarded operant responding of rats
Psychopharmacology (Berlin)
Effects of apomorphine on self-stimulation behavior
Psychopharmacologia
Review: D1 dopamine receptor—the search for a function: A critical evaluation of the dopamine receptor classification and its functional implications
Synapse
Fitting intracranial self-stimulation data with growth models
Behav. Neurosci.
Acute and chronic effects of psychoactive drugs on PFC self-stimulation
Soc. Neurosci. Abstr.
Cited by (25)
Differential effects of dopamine receptor subtype-specific agonists with respect to operant behavior maintained on a differential reinforcement of low-rate responding (DRL) schedule
2015, Pharmacology Biochemistry and BehaviorCitation Excerpt :Moreover, if we take the null result of PD168077 on DRL behavior into account, it is clear that the operant behavior task used in the present study can be used to screen drugs classified as selective DA receptor agonists. Furthermore, as observed in several other types of behavioral measurement with respect to psychopharmacology, the effects of direct/selective DA receptor agonist are known to be different to those of amphetamine; specifically, the operant responding to conditioned reward (Sutton and Benninger, 1999), to risk-based decision making (St. Onge and Floresco, 2009), and to intracranial self-stimulation (Baldo et al., 1999; Hunt et al., 1994). In addition, it is interesting to point out that the peak time measured in this study was unaffected by any of the tested DA receptor agonists.
Prenatal Exposure to Cocaine Increases the Rewarding Potency of Cocaine and Selective Dopaminergic Agonists in Adult Mice
2008, Biological PsychiatryCitation Excerpt :Although most investigators agree that BSR threshold is elevated by systemic administration of the selective D1 antagonist SCH-23390, findings are inconsistent among the few studies that have examined the effect of systemically-administered D1 agonists on ICSS. Reports have shown decreased ICSS after SKF-38393 administration in a reward-summation procedure (44) and increased BSR threshold after SKF-81297 administration with a rate-independent method (45), whereas others have shown decreased BSR threshold with SKF-38393 (46) and A-77636 (47) with the curve-shift method that we employ. We previously demonstrated in Swiss-Webster mice that systemic administration of SKF-82958 lowers BSR threshold in a dose-dependent manner (31).
Decreased sensitivity to the effects of dopamine D1-like, but not D2-like, receptor antagonism in the posterior hypothalamic region/anterior ventral tegmental area on brain reward function during chronic exposure to nicotine in rats
2005, Brain ResearchCitation Excerpt :Evidence indicates that D1-like receptors play a pivotal role in the reinforcing effects of ICSS. For example, prior research showed that SCH 23390 administered systemically decreased the reinforcing effects of ICSS [3,19,22,50]. Conversely, treatment with the D1-like receptor agonists SKF 38393 and A-77636 has been shown to potentiate brain reward function as assessed with the ICSS procedure [47,59].
Histaminergic systems of the limbic complex on learning and motivation
2001, Behavioural Brain Research
- 2
Present address: Research Laboratories, Astra Alab AB, Södertäje, Sweden